Biohaven Oral Presentation at ASN Kidney Week 2026 Spotlights BHV-1420, a Novel TRAP Degrader Designed to Selectively Remove the Autoantibodies that Drive Membranous Nephropathy
Key Highlights
- ➤BHV-1420 drove 88% of anti-PLA2R-positive patient samples below diagnostic positivity threshold
- ➤Single 4.8 mg/kg mouse dose achieved >90% anti-PLA2R depletion within two hours
- ➤BHV-1420 sustained >90% circulating anti-PLA2R depletion through 72-hour mouse study
- ➤BHV-1420 expands Biohaven’s TRAP nephrology franchise as its second kidney-disease program
- ➤BHV-1420 remains preclinical; safety and efficacy have not been established
Expert Statements
Tova Gardin, Chief Translational Officer of Biohaven
“Last year, our TRAP degrader approach to IgA nephropathy was highlighted in the opening plenary at Kidney Week. This year we are back at ASN with BHV-1420, the second TRAP degrader in our nephrology franchise”
Tova Gardin, Chief Translational Officer of Biohaven
“Our approach to membranous nephropathy exemplifies the promise of precision immunology to redefine how we treat immune-mediated disease, moving towards a future in which patients can address their disease at its source, free of the burden of broad immunosuppression.”
Tova Gardin, Chief Translational Officer of Biohaven
“It is in many ways the textbook case for our technology.”
Tova Gardin, Chief Translational Officer of Biohaven
“The disease-driving autoantibody is known, it is measured with a routine blood test, and its levels track with disease activity.”
Tova Gardin, Chief Translational Officer of Biohaven
“Yet, patients are still treated with broad immunosuppression.”
Tova Gardin, Chief Translational Officer of Biohaven
“BHV-1420 is designed to selectively remove the autoantibody that drives the disease with no impact on the broader immune system or immunoglobin repertoire.”
Tova Gardin, Chief Translational Officer of Biohaven
“That is the promise of the platform we licensed from Yale and have progressed from the Spiegel laboratory into patients.”
Tova Gardin, Chief Translational Officer of Biohaven
“It is why we see nephrology as a natural home for a franchise of precision degraders.”
David Pirman, Executive Vice President and Head of Discovery at Biohaven
“BHV-1420 shows how modular the TRAP platform is,”
David Pirman, Executive Vice President and Head of Discovery at Biohaven
“We engineered and optimized one end of the molecule to recognize the anti-PLA2R autoantibodies found in patients and the other to hand them off to the liver for degradation.”
David Pirman, Executive Vice President and Head of Discovery at Biohaven
“Tested against patient samples in a clinical diagnostic assay, BHV-1420 brought 88% of positive samples below the threshold for positivity.”
David Pirman, Executive Vice President and Head of Discovery at Biohaven
“In mice, it rapidly cleared circulating anti-PLA2R antibody after subcutaneous dosing.”
David Pirman, Executive Vice President and Head of Discovery at Biohaven
“Dr. Edward deRamon and our team have built exactly the profile we set out to engineer.”
Biohaven Oral Presentation at ASN Kidney Week 2026 Spotlights BHV-1420, a Novel TRAP Degrader Designed to Selectively Remove the Autoantibodies that Drive Membranous Nephropathy PR Newswire
One year after Biohaven's first TRAP degrader, BHV-1400, was highlighted in the Kidney Week opening plenary, Biohaven's second TRAP degrader for kidney disease expands its Yale-licensed platform into a growing nephrology franchise
Get started
Create a free account to read the full story.